author-photo

Christina Matheny

Genentech

14

Papers

316

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (1)
1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (118)
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (49)
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

2018 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (37)
OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)